Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shox2 morpholino is a synthetic antisense oligonucleotide used as a research tool to knock down the expression of the Short stature homeobox 2 (shox2) gene. Morpholinos function by binding to complementary sequences of RNA, typically blocking the translation initiation complex or interfering with pre-mRNA splicing. In developmental biology, particularly in zebrafish models, shox2 morpholinos are employed to investigate the gene's role in the development of the heart, brain, and limbs. Research has indicated that shox2 deficiency leads to altered expression of fibroblast growth factor receptor 3 (fgfr3) and natriuretic peptides, providing insights into conditions like short stature and cardiac stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shox2 morpholino.